Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
acid, acidity, AMP, ascent, assumption, benchmark, Biden, biotech, BTIG, Canaccord, comparison, consummate, consummated, consummation, counterparty, departure, dissolution, divestiture, effectuated, Extraordinary, fraction, fractional, Genuity, HHS, hybrid, IRA, irrevocably, Jaeger, lactate, lactic, lethal, LifeSci, malignant, multiplied, opposed, outpace, paper, paused, penalize, PET, ph, presidential, pursuit, Raven, readout, real, Rescue, scan, slate, stressful, therewith, thirteen, Ukraine, unrealized, weekly
Removed:
adding, apparent, attracting, Avenue, bid, borrow, capitalized, Carlton, chosen, closed, concentration, consumed, controlled, damage, defend, dense, disposition, Distinguishing, explore, formally, freestanding, grow, guide, hand, Hedging, House, hydrogen, indexed, invest, lease, leasehold, lived, mechanical, morbidity, mortality, Obama, observance, obstacle, passed, permanent, prescribed, progression, puttable, redeemable, removed, replacing, reproducing, resistance, secondary, spend, statistically, stream, susceptible, suspended, tolerability, undertaken, underwriter, underwriting, viability, water
Filing tables
Filing exhibits
CRVO similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements (Nos. 333-206408, 333-206409, 333-218060, 333-2267182, 333-233381, 333-238233, 333-258760 and 333-266827) on Form S-8, (Nos. 333-222203, 333-233686, 333-234234, 333-235670, and 333-238818) on Form S-1, and (Nos. 333-218062, 333-222879, 333-231541, and 333-249057) on Form S-3 of our report dated March 24, 2023, with respect to the consolidated financial statements of Diffusion Pharmaceuticals Inc.
/s/ KPMG LLP |
McLean, Virginia
March 24, 2023